Passage Bio, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PASG | SIGHT.PA | VYGR | ABVC | GANX | NRSN | |
|---|---|---|---|---|---|---|
| Market cap | 11.29M | 17.24M | 115.23M | 26.69M | 48.44M | 2.69M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.3 | -0.1 | -1.5 | -2.3 | -1.6 | -0.3 |
| Price/book | 2.5 | -0.5 | 0.7 | 2.5 | 4.3 | -1.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −49.25% | −48.74% | −57.14% | −65.92% | −37.50% | −93.90% |
| Today | +3.24% | +1.59% | +2.19% | +1.51% | −3.48% | +9.23% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PASG news ›Passage Bio (PASG) Set to Post Quarterly Earnings on Monday
Posted by Mitch Edgeman on Nov 2nd, 2026 Passage Bio (NASDAQ:PASG – Get Free Report) is anticipated to announce its Q3 2026 resultson Monday, November 9th. Analysts expect Passage Bio to post earnings of ($2.43) per share for the quarter.…
PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders
The proposed transaction may contain terms that could limit superior competing offers. NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigati
Passage Bio, Inc. (NASDAQ:PASG) Stock Now Rated “Hold” by Sell-Side Analysts
Posted by Danessa Lincoln on Oct 13th, 2026 PASG has been the subject of several recent analyst reports. Wall Street Zen downgraded shares of Passage Bio from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th.…
A proposed 1-for-2 to 1-for-10 reverse split faces a vote in Passage Bio (PASG)'s Remix merger.
Passage Bio (PASG) is a clinical stage genetic medicines company developing one-time gene therapies for neurodegenerative diseases, led by PBFT02 for frontotemporal dementia. - [S-4/A] Passage BIO, Inc. Amended Business Combination…
[EFFECT] Passage BIO, Inc. SEC Filing
Passage BIO, Inc. SEC Filing (Oct 13, 2026) Stock Titan [EFFECT] Passage BIO, Inc. SEC Filing Sentiment and the balance of points Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5…
Remix holders would own about 65% after the proposed Passage Bio (PASG) merger.
Passage Bio (PASG) is a clinical stage genetic medicines company developing one-time gene therapies for neurodegenerative diseases, led by PBFT02 for frontotemporal dementia. - [424B3] Passage BIO, Inc. Prospectus Filed Pursuant to Rule…
Passage Bio (NASDAQ:PASG) Stock Falls 2.4% – Here’s What Happened
Posted by Defense World Staff on Oct 11th, 2026 Passage Bio, Inc. (NASDAQ:PASG – Get Free Report) shares traded down 2.4% during mid-day trading on Friday. The stock traded as low as $3.61 and last traded at $3.69. Approximately 12,111…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net2
- themarketsdaily.com2
- businesswire.com1
- defenseworld.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.